Histological, molecular and functional subtypes of breast cancers

Increased understanding of the molecular heterogeneity that is intrinsic to the various subtypes of breast cancer will likely shape the future of breast cancer diagnosis, prognosis, and treatment. Advances in the field over the last several decades have been remarkable and have clearly translated into better patient care as evidenced by the earlier detection, better prognosis, and new targeted therapies. There have been two recent advances in the breast cancer research field that have lead to paradigm shifts: first, the identification of intrinsic breast tumor subtypes, which has changed the way we think about breast cancer and second, the recent characterization of cancer stem cells (CSCs), which are suspected to be responsible for tumor initiation, recurrence and resistance to therapy, have opened new exciting avenues to think about breast cancer therapeutic strategies. While these advances constitute major paradigm shifts within the research realm, the clinical arena has yet to adopt and apply our understanding of the molecular basis of the disease to early diagnosis, prognosis and therapy of breast cancers. Here, we will review the current clinical approach to classification of breast cancers, newer molecular-based classification schemes, and potential future of biomarkers representing a functional classification of breast cancer.

[1]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Sherlock,et al.  The prognostic role of a gene signature from tumorigenic breast-cancer cells. , 2007, The New England journal of medicine.

[3]  Gregory Y. Lauwers,et al.  Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast , 2009 .

[4]  T. Taguchi,et al.  Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers , 2009, Clinical Cancer Research.

[5]  Haiyan I. Li,et al.  Purification and unique properties of mammary epithelial stem cells , 2006, Nature.

[6]  Recommendations for the reporting of breast carcinoma. Association of Directors of Anatomic and Surgical Pathology. , 1995, American journal of clinical pathology.

[7]  Kornelia Polyak,et al.  Heterogeneity for Stem Cell–Related Markers According to Tumor Subtype and Histologic Stage in Breast Cancer , 2010, Clinical Cancer Research.

[8]  J. Whitesides,et al.  Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[9]  R. Bast,et al.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  K. Friedrichs,et al.  High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. , 1995, Cancer research.

[11]  Emad A. Rakha,et al.  Combinatorial biomarker expression in breast cancer , 2010, Breast Cancer Research and Treatment.

[12]  B. Iacopetta,et al.  Reply to C. Badoual et al , 2009 .

[13]  V. Band,et al.  Telomerase-immortalized human mammary stem/progenitor cells with ability to self-renew and differentiate , 2010, Proceedings of the National Academy of Sciences.

[14]  O. Colvin,et al.  Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  François Vaillant,et al.  Generation of a functional mammary gland from a single stem cell , 2006, Nature.

[16]  Recommendations for the reporting of breast carcinoma. Association of Directors of Anatomic and Surgical Pathology. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[17]  P. Pelicci,et al.  Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content , 2010, Cell.

[18]  Carlos Caldas,et al.  Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis , 2007, Nature Reviews Cancer.

[19]  S. Salani,et al.  Identification of a Primitive Brain–Derived Neural Stem Cell Population Based on Aldehyde Dehydrogenase Activity , 2006, Stem cells.

[20]  Yun Yen,et al.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[21]  M. Lagios,et al.  Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence , 1989, Cancer.

[22]  D N Poller,et al.  Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[23]  C. Wells,et al.  Predictive markers in breast cancer – the present , 2007, Histopathology.

[24]  Christos Hatzis,et al.  Commercialized multigene predictors of clinical outcome for breast cancer. , 2008, The oncologist.

[25]  Donald L Weaver,et al.  Protocol for the examination of specimens from patients with invasive carcinoma of the breast. , 2009, Archives of pathology & laboratory medicine.

[26]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[28]  L. Arrighi,et al.  [Treatment of breast cancer]. , 1971, Prensa medica argentina.

[29]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[30]  J. Visvader,et al.  Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. , 2009, Genes & development.

[31]  M. J. Silverstein,et al.  Prognostic classification of breast ductal carcinoma-in-situ , 1995, The Lancet.

[32]  J. Nolta,et al.  Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. , 2004, Blood.

[33]  M. J. van de Vijver,et al.  Ductal carcinoma in situ: a proposal for a new classification. , 1994, Seminars in diagnostic pathology.

[34]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[35]  J. Daling,et al.  Clinical characteristics of different histologic types of breast cancer , 2005, British Journal of Cancer.

[36]  G. Smith,et al.  An entire functional mammary gland may comprise the progeny from a single cell. , 1998, Development.

[37]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[38]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  S. Fox,et al.  Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers , 2009, Nature Medicine.

[40]  S. Agarwal,et al.  In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. , 2010, The American journal of pathology.

[41]  J. Reis-Filho,et al.  Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment , 2010, Breast Cancer Research and Treatment.

[42]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[43]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.